Pfizer and Celltrion win cell-culture spat

Pfizer’s Hospira and its biosimilar development partner Celltrion have won a summary judgement from a Massachusetts district court affirming that the cell-culture media they use to produce the Inflectra/Remsima (infliximab-dyyb) biosimilar does not infringe Janssen’s US patent 7,598,083 under the doctrine of equivalents.